{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:54:55Z","timestamp":1785902095280,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.oret.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:17:20Z","timestamp":1773130640000},"page":"753-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medicare Trends in Intravitreal Anti-VEGF Use"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-3215","authenticated-orcid":false,"given":"Salem","family":"Abu Al-Burak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9808-038X","authenticated-orcid":false,"given":"Justin","family":"Shad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-0759","authenticated-orcid":false,"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev H.","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.03.006_bib1","doi-asserted-by":"crossref","DOI":"10.5493\/wjem.v14.i4.99235","article-title":"Intravitreal therapy for the management of diabetic retinopathy: a concise review","volume":"14","author":"Arora","year":"2024","journal-title":"World J Exp Med"},{"key":"10.1016\/j.oret.2026.03.006_bib2","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.2147\/OPTH.S489114","article-title":"Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review","volume":"18","author":"Aldokhail","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1017889","article-title":"Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"13","author":"Ma","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oret.2026.03.006_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.oret.2023.06.009","article-title":"Detection and management of intraocular inflammation after brolucizumab treatment for neovascular age-related macular degeneration","volume":"7","author":"Bodaghi","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.03.006_bib5","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.3390\/jcm13175208","article-title":"Inflammation and vasculitis related to brolucizumab","volume":"13","author":"Campos","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.oret.2026.03.006_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2014-305041","article-title":"Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel","volume":"99","author":"Gerding","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.03.006_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2040622312446007","article-title":"Aflibercept in wet age-related macular degeneration: a perspective review","volume":"3","author":"Ohr","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.oret.2026.03.006_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/eye.2014.308","article-title":"Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA","volume":"29","author":"Lotery","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.03.006_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197670","article-title":"The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective","volume":"13","author":"van Asten","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2026.03.006_bib11","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/s41433-020-01227-w","article-title":"Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.03.006_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/ph18111620","article-title":"Effectiveness, safety, and real-world experience of brolucizumab: a systematic review","volume":"18","author":"Alali","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.oret.2026.03.006_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema","volume":"260","author":"Wykoff","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib15","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2147\/OPTH.S424314","article-title":"One year results of faricimab for aflibercept-resistant diabetic macular edema","volume":"17","author":"Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.oret.2026.03.006_bib17","article-title":"Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations","volume":"10","author":"Wong","year":"2025","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.03.006_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100111","article-title":"YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale","volume":"2","author":"Eter","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2026.03.006_bib20","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.oret.2026.03.006_bib21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/09286586.2024.2310854","article-title":"Trends in anti-vascular endothelial growth factor original Medicare Part B claims in the United States, 2014-2019","volume":"31","author":"Desai","year":"2024","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.oret.2026.03.006_bib22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamaophthalmol.2019.1971","article-title":"Analysis of anti-vascular endothelial growth factor injection claims data in US Medicare Part B beneficiaries from 2012 to 2015","volume":"137","author":"Berkowitz","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.03.006_bib24","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40123-024-00920-3","article-title":"Real-world safety outcomes with brolucizumab in neovascular age-related macular degeneration: findings from the IRIS\u00ae Registry","volume":"13","author":"Zarbin","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.oret.2026.03.006_bib25","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.oret.2026.03.006_bib27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","article-title":"Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis","volume":"67","author":"Im","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archophthalmol.2007.53","article-title":"Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) project","volume":"126","author":"Bressler","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib29","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ophtha.2016.02.015","article-title":"High variation of intravitreal injection rates and Medicare anti-vascular endothelial growth factor payments per injection in the United States","volume":"123","author":"Erie","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.03.006_bib30","first-page":"451","article-title":"Assessing variation in US payer coverage of anti-vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema","volume":"31","author":"Chambers","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.oret.2026.03.006_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055478","article-title":"Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013-2018): a retrospective analysis of administrative data","volume":"12","author":"Rocha","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.oret.2026.03.006_bib32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2026.03.006_bib33","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/eye.2017.81","article-title":"Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option","volume":"31","author":"Ashraf","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.03.006_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.2951","article-title":"Medicare Part B spending on macular degeneration treatments associated with manufacturer payments to ophthalmologists","volume":"4","author":"Dickson","year":"2023","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.oret.2026.03.006_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajo.2018.04.008","article-title":"Estimating Medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration","volume":"191","author":"Rosenfeld","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib36","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ophtha.2023.04.019","article-title":"The biosimilar paradox: how anti-vascular endothelial growth factor biosimilars could increase patient and overall health care costs","volume":"130","author":"Zhang","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.03.006_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/aes-24-33","article-title":"The impact potential of aflibercept biosimilars","volume":"10","author":"Delaney","year":"2025","journal-title":"Ann Eye Sci"},{"key":"10.1016\/j.oret.2026.03.006_bib38","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-vascular endothelial growth factor biosimilars in ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.03.006_bib39","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.03.006_bib40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2026.03.006_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-17378-3","article-title":"Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration","volume":"15","author":"Masaoka","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2026.03.006_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoint.2025.100132","article-title":"Short-term outcomes of faricimab and aflibercept 8 mg in diabetic macular edema","volume":"2","author":"Maccauro","year":"2025","journal-title":"AJO Int"},{"key":"10.1016\/j.oret.2026.03.006_bib43","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s40123-025-01247-3","article-title":"Aflibercept 8 mg versus faricimab treat-and-extend for diabetic macular edema or neovascular age-related macular degeneration: a Bayesian fixed-effect network meta-analysis of clinical trials","volume":"14","author":"Friedman","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.oret.2026.03.006_bib44","first-page":"476","article-title":"Factors associated with success of switching to faricimab for neovascular age-related macular degeneration refractory to intravitreal aflibercept","volume":"14","author":"Machida","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.oret.2026.03.006_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jclinepi.2004.06.002","article-title":"A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors","volume":"58","author":"Schneeweiss","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.oret.2026.03.006_bib46","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1176\/appi.ps.201200186","article-title":"How quickly do physicians adopt new drugs? The case of second-generation antipsychotics","volume":"64","author":"Huskamp","year":"2013","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.oret.2026.03.006_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204826","article-title":"Influence of peer networks on physician adoption of new drugs","volume":"13","author":"Donohue","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2026.03.006_bib48","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaophthalmol.2016.1678","article-title":"Physician-industry interactions and anti-vascular endothelial growth factor use among US ophthalmologists","volume":"134","author":"Taylor","year":"2016","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302600103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302600103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:38:26Z","timestamp":1785901106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865302600103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S246865302600103X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.03.006","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicare Trends in Intravitreal Anti-VEGF Use","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}